An important end point for many cancer chemotherapy trials is the development of toxic effects. Standard data collection forms capture these data from clinicians but not from patients. Falchook et al examined toxicity data reported by clinicians and patients from a phase 2 clinical trial of deintensified chemoradiotherapy for oropharyngeal cancer. They found a significant decline in agreement between clinician and patient reports as toxic effects developed and that clinicians reported lower severity of toxic effects than did patients. This suggests that the inclusion of patient-reported symptoms and toxic effects can improve the quality of clinical trials and patient care. Worden provides an Invited Commentary.
Highlights. JAMA Otolaryngol Head Neck Surg. 2016;142(6):511. doi:10.1001/jamaoto.2015.1809